# CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk

> **NCT07053462** · PHASE1,PHASE2 · RECRUITING · sponsor: **AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC** · enrollment: 90 (estimated)

## Conditions studied

- End-Stage Renal Disease
- End Stage Renal Disease on Dialysis
- End Stage Renal Disease With Renal Transplant
- Kidney Transplant Rejection
- Kidney Tumor
- Kidney Failure
- Kidney Ischemia

## Interventions

- **BIOLOGICAL:** Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney
- **PROCEDURE:** Kidney Transplantation with Standard Care

## Key facts

- **NCT ID:** NCT07053462
- **Lead sponsor:** AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2027-12-18
- **Final completion:** 2028-12-28
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07053462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07053462, "CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07053462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*